{"id":8049,"date":"2026-10-25T12:20:08","date_gmt":"2026-10-25T18:20:08","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=8049"},"modified":"2026-10-25T12:38:45","modified_gmt":"2026-10-25T18:38:45","slug":"the-never-ending-tavneos-story","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2026\/10\/25\/8049\/the-never-ending-tavneos-story\/","title":{"rendered":"The Never-Ending TAVNEOS Story"},"content":{"rendered":"\n<figure class=\"wp-block-image alignwide size-full\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"149\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?resize=530%2C149&#038;ssl=1\" alt=\"\" class=\"wp-image-8058\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?w=640&amp;ssl=1 640w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?resize=300%2C84&amp;ssl=1 300w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Tavneos story is getting more bizarre by the day:&nbsp; since January 2026 FDA is haggling with Amgen about a withdrawal.&nbsp; The Agency\u2019s reasoning is described in detail in their April 26 statement and mentioned in numerous Pharma newsletters.&nbsp; The key issue is and was the unblinded re-adjudication of the pivotal ADVANCE study data, making the outcome look superior in the avacopan arm.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In an effort to keep Tavneos on the market, Amgen argues that the drug is safer than portrayed by FDA.&nbsp; The company also believes it is efficacious in ANCA vasculitis based on the \u2018totality of the data\u2019 which include post-marketing trials and patient testimonials.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Amgen asked DCRI for an independent review of the ADVANCE study data.&nbsp; This effort backfired: DCRI\u2019s assessment did not support the re-adjudicated analysis; instead, it confirmed the original analysis which showed no superiority over the comparison arm.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As we explained in an earlier blog (<a href=\"https:\/\/allphasepharma.com\/dir\/2026\/07\/14\/7499\/avacopan-advocate-study-design\/\" data-type=\"link\" data-id=\"https:\/\/allphasepharma.com\/dir\/2026\/07\/14\/7499\/avacopan-advocate-study-design\/\">https:\/\/allphasepharma.com\/dir\/2026\/07\/14\/7499\/avacopan-advocate-study-design\/<\/a>), there was a trend in favor of avacopan in the subgroup of patients.\u00a0 However, the control arm in this group received only short-term Rituxan without immune suppression for the rest of the year.\u00a0 We felt that this study design was seriously biased; since then, we learned that the FDA had similar concerns.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Amgen\u2019s lawyers produced a lengthy, legalistic and highly sophistic document arguing that re-adjudication of data is not unheard of in the world of NDA submissions. They defended the actions of Chemocentryx as being merely a sign of a thorough data cleaning effort.\u00a0 According to them, flipping the outcomes of a handful of cases after unblinding is not unheard of.\u00a0 They argued that there was no need to inform FDA of these steps, which they presented as routine, well-intentioned company QC practices.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the meantime, mainly based on the FDA April 26 report, regulatory agencies all over the world have stopped the marketing authorization of Tavneos.&nbsp; A few days ago, CHMP released an assessment report, which clearly explains why the approval was revoked in Europe.&nbsp; The UK\u2019s MHRA allows no new patients and with a full withdrawal period in early 2027 when the drug approval will be rescinded.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">So, what is the FDA waiting for?\u00a0 The drug is in limbo, and so are patients and caregivers.\u00a0 We can only speculate but have a sinister hunch too.\u00a0 Let\u2019s go over the most plausible reasons in the form of a multiple choice questionnaire for your input (feel free to add your reason if not listed):<\/p>\n\n\n<div class=\"dem-poll-shortcode\">\n<style id=\"democracy-poll-css\">.democracy{display:flow-root}.democracy[class]{:where(ul,ul li){background:0 0;padding:0;margin:0}:where(ul){list-style:none;border:none}:where(ul li){list-style:none}:where(ul li):before{display:none}:where(input[type=radio]),:where(input[type=checkbox]){margin:0;vertical-align:middle;&:focus{outline:none}}}.dem-button{position:relative;display:inline-block;line-height:1;border:0;margin:0;padding:0;text-decoration:none;cursor:pointer;white-space:nowrap;user-select:none;&:focus{outline:none}&:disabled{opacity:.6;cursor:not-allowed}&:hover{text-decoration:none !important}}.democracy{--dem-graph-bg:transparent;--dem-graph-color:rgba(0,0,0,.6);--dem-graph-height:1.2em;--dem-star-color:#ff4e00;--dem-fill-color:#7cb4dd;--dem-fill-voted-color:#FFC45A;position:relative;margin:0 auto;:where(input[type=radio],input[type=checkbox]){margin-right:.2em}ul.dem-vote{margin-bottom:1em;li{padding-bottom:0;margin-bottom:0}li>*{margin-bottom:.6em}}ul.dem-answers{li{padding-bottom:1em}}}.dem-screen{position:relative;line-height:1.3}.dem-answers{.dem-label{margin-bottom:.2em;line-height:1.2}}.dem-graph{position:relative;box-sizing:content-box;display:table;width:100%;height:var(--dem-graph-height);line-height:var(--dem-graph-height);background:var(--dem-graph-bg);color:var(--dem-graph-color)}.dem-fill{position:absolute;top:0;left:0;height:100%;background-color:var(--dem-fill-color)}.dem-voted-this .dem-fill{background-color:var(--dem-fill-voted-color)}.dem-votes-txt,.dem-percent-txt{position:relative;display:table-cell;padding-left:.3em;vertical-align:middle;font-size:90%}.dem-poll-info{display:flex;flex-direction:column;gap:.2em;font-size:85%;>*{display:block;text-align:right;opacity:.7}}.dem-vote{label{display:flex;align-items:center;gap:.5em;.dem__spot{flex-shrink:0}}.dem-disabled{opacity:.5}}.dem-results-link{display:inline-block;margin:.8em 1em}.dem-bottom{display:flex;flex-direction:column;flex-wrap:wrap;gap:1em;text-align:center;margin-bottom:1em}.dem-poll-title{display:block;margin-bottom:1.5em;margin-top:1.2em;font-size:120%}.dem-star{font-size:90%;vertical-align:baseline;padding-left:.3em;color:var(--dem-star-color)}.dem-poll-note{font-size:90%;padding:.5em;opacity:.8;line-height:1.3}.dem-notice-inline{width:100%;padding:1.5em 2em;box-sizing:border-box;border-radius:2px;text-align:center;background:rgba(247 241 212\/.15)}.dem-notice{z-index:10;position:absolute;top:0;width:100%;padding:1.5em 2em;box-sizing:border-box;border-radius:2px;text-align:center;background:rgba(247,241,212,0.8);color:#6D6214;a{color:#423b08;text-decoration:underline}}.dem-notice-close{position:absolute;top:0;right:0;padding:5px;cursor:pointer;line-height:.6;font-size:150%;border:0;background:none;color:inherit;&:hover{color:#d26616}}.dem-add-answer{position:relative;>*{display:block}a{display:inline-block}}input:where(.dem-add-answer-txt){width:100%;box-sizing:border-box;padding:.2em .3em;font-size:100%}.dem-add-answer-close{position:absolute;right:0;padding:0 .7em;cursor:pointer;color:#333;&:hover{color:#ff2700}}.dem-edit-link{display:block;position:absolute;top:0;right:0;line-height:1;text-decoration:none !important;border:none !important;svg{width:1.2em!important;fill:#6c6c6c}&:hover svg{fill:#35a91d}}.dem-loader{display:none;position:absolute;top:0;left:0;width:100%;height:100%;>*{display:table-cell;vertical-align:middle;text-align:center}svg{width:20%;max-width:100px;min-width:80px;margin-bottom:15%}[class^=dem-]{margin-bottom:15%}}.dem__collapser{display:block;cursor:pointer;text-align:center;font-size:150%;line-height:1;&:hover{color:#f31;background:rgba(255,255,255,.3)}&.expanded{position:relative;height:1em}&.collapsed{position:absolute;top:0;bottom:0;right:0;left:0}.arr{display:block;position:absolute;bottom:0;width:100%}&.collapsed .arr:before{content:\"\u25be\"}&.expanded .arr:before{content:\"\u25b4\"}}.dem-poll-shortcode{margin-bottom:1.5em}.dem-archives{.dem-elem-wrap{margin-bottom:2em;padding-bottom:20px;border-bottom:1px dashed rgba(0,0,0,.1)}.dem-archive-link{display:none}}.dem-moreinfo{padding:1em 1.5em;background:rgba(0 0 0\/.15);&>*:last-child{margin-bottom:0}}.dem-paging{text-align:center;margin:1.5em auto;>*{display:inline-block;padding:.3em .8em;border-radius:.2em;background:#e2e2e2;color:#333;text-decoration:none;text-transform:lowercase;user-select:none}>a{color:#333}>a:hover{background:#ccc;color:#333;text-decoration:none}.current{background:#656565;color:#fff}.dots{background:0 0}}.democracy{--dem-graph-bg:linear-gradient(to bottom,rgba(0,0,0,.05) 50%,rgba(0,0,0,.1) 50%)}.dem-link{font-style:italic;font-size:90%}.dem-vote-link:before{content:'\u25c2 '}.dem-vote label:hover{opacity:.8}.dem-vote-bottom{flex-direction:row;justify-content:space-between}.dem-fill{background-image:linear-gradient(to right,rgba(255,255,255,.3),transparent)}.dem-answers .dem-label{margin-bottom:.1em}.dem-votes-txt,.dem-percent-txt{font-size:80%}.dem-percent-txt{display:none}.dem-answers li:hover .dem-votes-txt{display:none}.dem-answers li:hover .dem-percent-txt{display:table-cell}.dem-voted-this{font-weight:bold;.dem-label:before{content:'\u2713';display:inline-block;margin-right:.2em}}.dem-label-percent-txt,.dem-votes-txt-percent,.dem-novoted .dem-votes-txt{display:none}.dem-poll-info{font-style:italic}.dem-archive-link{text-align:right}.dem-bottom{text-align:left}.dem-button[class]{font-size:90%;font-family:tahoma,arial,sans-serif;padding:.8em 1.6em;color:var(--dem-button-color,#fff);background:var(--dem-button-bg,#61a9de);text-transform:uppercase}.dem-button[class]:hover{color:var(--dem-button-hover-color,var(--dem-button-color,#fff));background:var(--dem-button-hover-bg,#3b8bc6)}.dem-button[class]:visited{color:var(--dem-button-color,#fff)}<\/style>\n\n<div class=\"dem-loader dem_loader_js\"><div><style type=\"text\/css\">\n.dem-roller {\n  margin: 0 auto;\n  width: 40px;\n  height: 40px;\n  position: relative;\n}\n\n.con1 > div, .con2 > div, .con3 > div {\n  width: 10px;\n  height: 10px;\n  background-color: var(--dem-loader-color, #2686cc);\n\n  border-radius: 100%;\n  position: absolute;\n  animation: bouncedelay 1.2s infinite ease-in-out;\n  \/* Prevent first frame from flickering when animation starts *\/\n  animation-fill-mode: both;\n}\n\n.dem-roller .demrcont {\n  position: absolute;\n  width: 100%;\n  height: 100%;\n}\n\n.con2 {\n  transform: rotateZ(45deg);\n}\n\n.con3 {\n  transform: rotateZ(90deg);\n}\n\n.circle1 { top: 0; left: 0; }\n.circle2 { top: 0; right: 0; }\n.circle3 { right: 0; bottom: 0; }\n.circle4 { left: 0; bottom: 0; }\n\n.con2 .circle1 { animation-delay: -1.1s; }\n.con3 .circle1 { animation-delay: -1.0s; }\n.con1 .circle2 { animation-delay: -0.9s; }\n.con2 .circle2 { animation-delay: -0.8s; }\n.con3 .circle2 { animation-delay: -0.7s; }\n.con1 .circle3 { animation-delay: -0.6s; }\n.con2 .circle3 { animation-delay: -0.5s; }\n.con3 .circle3 { animation-delay: -0.4s; }\n.con1 .circle4 { animation-delay: -0.3s; }\n.con2 .circle4 { animation-delay: -0.2s; }\n.con3 .circle4 { animation-delay: -0.1s; }\n@keyframes bouncedelay {\n  0%, 80%, 100% { \n    transform: scale(0.0);\n  } 40% { \n    transform: scale(1.0);\n  }\n}\n<\/style>\n\n<div class=\"dem-roller\">\n  <div class=\"demrcont con1\">\n    <div class=\"circle1 css-fill\"><\/div>\n    <div class=\"circle2 css-fill\"><\/div>\n    <div class=\"circle3 css-fill\"><\/div>\n    <div class=\"circle4 css-fill\"><\/div>\n  <\/div>\n  <div class=\"demrcont con2\">\n    <div class=\"circle1 css-fill\"><\/div>\n    <div class=\"circle2 css-fill\"><\/div>\n    <div class=\"circle3 css-fill\"><\/div>\n    <div class=\"circle4 css-fill\"><\/div>\n  <\/div>\n  <div class=\"demrcont con3\">\n    <div class=\"circle1 css-fill\"><\/div>\n    <div class=\"circle2 css-fill\"><\/div>\n    <div class=\"circle3 css-fill\"><\/div>\n    <div class=\"circle4 css-fill\"><\/div>\n  <\/div>\n<\/div>\n\n<\/div><\/div>\n<template class=\"dem_notice_template_js\">\n\t<div class=\"dem-notice dem_notice_js\">\n\t\t<button type=\"button\" class=\"dem-notice-close dem_notice_close_js\" aria-label=\"Close\">&times;<\/button>\n\t\t<div class=\"dem-notice-message dem_notice_message_js\"><\/div>\n\t<\/div>\n<\/template>\n<div id=\"democracy-1\" class=\"democracy democracy_js\" data-opts='{&quot;pid&quot;:1,&quot;max_answs&quot;:0,&quot;answs_max_height&quot;:&quot;&quot;,&quot;allow_same_ip_votes&quot;:0}' >\n\t<strong class=\"dem-poll-title\">Why is Tavneos still approved in the US?<\/strong>\n\t<div class=\"dem-screen vote dem_screen_js\"><div class=\"dem-vote-wrap dem_vote_wrap_js\" >\n\t<ul class=\"dem-vote dem_answers_list_js\">\n\t<li class=\"dem-answer-item dem_answer_item_js\" data-aid=\"4\">\n\t<label class=\"dem__radio_label\">\n\t\t<input class=\"dem__radio\" name=\"dem_group_p1\"  type=\"radio\" value=\"4\"  ><span class=\"dem__spot\"><\/span> FDA reviewers made a mistake and found the missing stats documents in the avacopan NDA filing just now\n\t<\/label>\n<\/li><li class=\"dem-answer-item dem_answer_item_js\" data-aid=\"5\">\n\t<label class=\"dem__radio_label\">\n\t\t<input class=\"dem__radio\" name=\"dem_group_p1\"  type=\"radio\" value=\"5\"  ><span class=\"dem__spot\"><\/span> A new FDA Guidance is in the works that permits post-marketing data for NDA approval\n\t<\/label>\n<\/li><li class=\"dem-answer-item dem_answer_item_js\" data-aid=\"3\">\n\t<label class=\"dem__radio_label\">\n\t\t<input class=\"dem__radio\" name=\"dem_group_p1\"  type=\"radio\" value=\"3\"  ><span class=\"dem__spot\"><\/span> FDA\u2019s Tavneos reviewer is on unpaid leave-of-absence\n\t<\/label>\n<\/li><li class=\"dem-answer-item dem_answer_item_js\" data-aid=\"2\">\n\t<label class=\"dem__radio_label\">\n\t\t<input class=\"dem__radio\" name=\"dem_group_p1\"  type=\"radio\" value=\"2\"  ><span class=\"dem__spot\"><\/span> A new FDA commissioner is about to be appointed, and things are deferred\n\t<\/label>\n<\/li><li class=\"dem-answer-item dem_answer_item_js\" data-aid=\"1\">\n\t<label class=\"dem__radio_label\">\n\t\t<input class=\"dem__radio\" name=\"dem_group_p1\"  type=\"radio\" value=\"1\"  ><span class=\"dem__spot\"><\/span> RFK Jr. is annoyed by the April 26 document calling it a woke compilation of factoids\n\t<\/label>\n<\/li><li class=\"dem-answer-item dem_answer_item_js\" data-aid=\"6\">\n\t<label class=\"dem__radio_label\">\n\t\t<input class=\"dem__radio\" name=\"dem_group_p1\"  type=\"radio\" value=\"6\"  ><span class=\"dem__spot\"><\/span> FDA wants to wait till Halloween for a real spooky news release\n\t<\/label>\n<\/li><li class=\"dem-answer-item dem_answer_item_js\" data-aid=\"7\">\n\t<label class=\"dem__radio_label\">\n\t\t<input class=\"dem__radio\" name=\"dem_group_p1\"  type=\"radio\" value=\"7\"  ><span class=\"dem__spot\"><\/span> There is a new indication for Tavneos for which it actually works\n\t<\/label>\n<\/li><li class=\"dem-add-answer dem_add_answer_item_js\">\n\t<a class=\"dem-link dem_link_js dem-add-answer-link dem_add_answer_link_js\" data-dem-act=\"newAnswer\" href=\"#\" rel=\"nofollow\">Add your answer<\/a>\n<\/li>\n<\/ul>\n\t<div class=\"dem-bottom dem-vote-bottom\">\n\t<div class=\"dem-vote-button dem_vote_button_js\" >\n\t<input class=\"dem-button \" type=\"button\" value=\"Vote\" data-dem-act=\"vote\">\n<\/div>\n<\/div><!--\/dem-bottom-->\n<\/div><\/div>\n<\/div><!--democracy-->\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Thank you in advance for your considered input &#8211; much appreciated!\u00a0 We will tally all responses and revert.\u00a0 We promise there will be no re-adjudication of the vote in any way.\u00a0\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We will release poll results after the November midterm elections as we don\u2019t want to influence the vote.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ABBREVIATIONS<\/strong><br \/>CHMP   Committee for Medicinal Products for Human Use<br \/>DCRI     Duke Clinical Research Institute<br \/>MHRA   Medicines and Healthcare Products Regulatory Agency<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Tavneos story is getting more bizarre by the day:&nbsp; since January 2026 FDA is haggling with Amgen about a withdrawal.&nbsp; The Agency\u2019s reasoning is described in detail in their April 26 statement and mentioned in numerous Pharma newsletters.&nbsp; The key issue is and was the unblinded re-adjudication of the <a class=\"more-link\" href=\"https:\/\/allphasepharma.com\/dir\/2026\/10\/25\/8049\/the-never-ending-tavneos-story\/\">Continue reading <span class=\"screen-reader-text\">  The Never-Ending TAVNEOS Story<\/span><span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":8058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[140,3,18],"tags":[2788,1271,2727,2239,2715,2728,2785,2789,2786,2741,625,5,2787,1583,2784,2716],"class_list":["post-8049","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interesting_facts","category-the_news","category-the_viewpoint","tag-advance-study","tag-allphase-pharma-consulting","tag-amgen","tag-anca-vasculitis","tag-avacopan","tag-chemocentryx","tag-chmp","tag-complement-c5ar-inhibitor","tag-data-re-adjudication","tag-dcri","tag-ema","tag-fda","tag-fda-inaction","tag-harald-reinhart","tag-mhra","tag-tavneos"],"jetpack_publicize_connections":[],"jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-25P","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":7655,"url":"https:\/\/allphasepharma.com\/dir\/2026\/08\/27\/7655\/avacopan-tavneos-follow-up\/","url_meta":{"origin":8049,"position":0},"title":"Avacopan \/ TAVNEOS Follow-Up","author":"Harald","date":"August 27, 2026","format":false,"excerpt":"There was not much for us to report on this summer that would interest our readership... Let\u2019s skip the Fauci \/ Paul senate drama regarding the origins of Covid, with senator Paul taking the role of the Grand Inquisitor and Dr. Fauci the Fifth. The latest act in this screen\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/08\/Avacopan-SLIDER-II-1024x288.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":7499,"url":"https:\/\/allphasepharma.com\/dir\/2026\/07\/14\/7499\/avacopan-advocate-study-design\/","url_meta":{"origin":8049,"position":1},"title":"Avacopan ADVOCATE Study Design","author":"Harald","date":"July 14, 2026","format":false,"excerpt":"Lopsided Avacopan ADVOCATE Study Design","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/07\/Avacopan-SLIDER.jpg?fit=1200%2C337&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/07\/Avacopan-SLIDER.jpg?fit=1200%2C337&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/07\/Avacopan-SLIDER.jpg?fit=1200%2C337&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/07\/Avacopan-SLIDER.jpg?fit=1200%2C337&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/07\/Avacopan-SLIDER.jpg?fit=1200%2C337&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4416,"url":"https:\/\/allphasepharma.com\/dir\/2025\/05\/30\/4416\/baff-april-inhibitors-homing-in-on-igan\/","url_meta":{"origin":8049,"position":2},"title":"BAFF \/ APRIL Inhibitors Homing in on IgAN","author":"Harald","date":"May 30, 2025","format":false,"excerpt":"Today we discuss the group of BAFF\/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical success has been seen only in IgA nephropathy (IgAN), with\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":8073,"url":"https:\/\/allphasepharma.com\/dir\/2026\/10\/27\/8073\/igan-therapy-its-getting-crowded-out-there\/","url_meta":{"origin":8049,"position":3},"title":"IgAN Therapy \u2013 It\u2019s Getting Crowded Out There","author":"Harald","date":"October 27, 2026","format":false,"excerpt":"Earlier this year, the NEJM published interim data on atacicept and sibeprenlimab in IgAN, both well-designed Phase 3 pivotal registration trials of promising drugs [1],[2]. Sponsors were clearly anxious to show the world how well their drug is working, but why publish interim results?\u00a0 After all, IA data are usually\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":2095,"url":"https:\/\/allphasepharma.com\/dir\/2015\/11\/03\/2095\/amdac-november-5-2015-on-fluoroquinolones-in-as-aecb-uuti-part-1\/","url_meta":{"origin":8049,"position":4},"title":"AMDAC November 5, 2015 on Fluoroquinolones in ABS, ABECB, uUTI\u00a0 &#8211; Part 1","author":"Harald","date":"November 3, 2015","format":false,"excerpt":"Only now, a few days before the actual AMDAC meeting, the\u00a0FDA\u2019s Briefing Document becomes available to the public.\u00a0 The topic of the December 5th meeting:\u00a0 Reappraisal of the risk\/benefit of fluoroquinolones (FQ) in approved but \u201cmild, self-limiting\u201d disease indications in light of new post-approval safety issues. The document is 617\u2026","rel":"","context":"In &quot;The News&quot;","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"AMDAC - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":6432,"url":"https:\/\/allphasepharma.com\/dir\/2026\/02\/25\/6432\/the-new-default-1-one-single-pivotal-trial\/","url_meta":{"origin":8049,"position":5},"title":"The New Default:  1 (One) Single Pivotal Trial","author":"Harald","date":"February 25, 2026","format":false,"excerpt":"Statements that have the words \u2018FDA\u2019 and \u2018flexibility\u2019 in a single sentence need to be approached with some skepticism.\u00a0 Especially if made by the Agency. \u2018Flexibility\u2019 always sounds better than \u2018less rigidity\u2019. Regulators are tasked with providing a certain sense of consistency or stability in the drug development jungle where\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/slot-machines-winning-three-FDA-e1771883436805.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/slot-machines-winning-three-FDA-e1771883436805.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/slot-machines-winning-three-FDA-e1771883436805.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/HR2_Dali-Surreal-Drug-Study-1.jpg?fit=640%2C180&ssl=1","_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/8049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=8049"}],"version-history":[{"count":8,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/8049\/revisions"}],"predecessor-version":[{"id":8062,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/8049\/revisions\/8062"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/8058"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=8049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=8049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=8049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}